Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat

Am J Physiol Renal Physiol. 2004 Jul;287(1):F81-9. doi: 10.1152/ajprenal.00349.2003. Epub 2004 Mar 23.

Abstract

The Wistar-Furth (WF) rat is protected against chronic renal disease (CRD) following 5/6th ablation/infarction vs. the Sprague-Dawley (SD) rat, and protection was associated with preserved renal nitric oxide (NO) production. This study examined CRD induced with repeated administration of puromycin aminonucleoside (PAN). SD PAN developed nephrotic range proteinuria (>1 g/24 h), and at 15 wk severe renal injury developed and the glomerular filtration rate (GFR) was reduced to approximately 10% of sham. Total NO production, renal NO synthase (NOS) activity, and renal neuronal (n) and medullary endothelial (e)NOS abundance were reduced in the SD PAN. WF PAN exhibited less severe initial proteinuria (>400 mg/24 h), which abated within weeks, whereas GFR was normal and injury was minimal at 15 wk. Total NO production and renal NOS activity and abundance were significantly elevated compared with SD PAN. NOS mRNA (nNOS, eNOS, and inducible NOS) was not altered in WF, whereas SD showed significant increases in NOS gene expression with PAN. In conclusion, WF showed resistance to a second model of CRD with maintained renal NOS activity compared with SD.

MeSH terms

  • Animals
  • Antimetabolites, Antineoplastic / toxicity*
  • Disease Models, Animal
  • Glomerular Filtration Rate
  • Kidney Failure, Chronic / physiopathology
  • Kidney Failure, Chronic / prevention & control*
  • Kidney Failure, Chronic / veterinary
  • Kidney Medulla / physiology
  • Male
  • Nitric Oxide / analysis
  • Nitric Oxide Synthase / pharmacology*
  • Puromycin Aminonucleoside / toxicity*
  • Rats
  • Rats, Inbred WF / physiology*

Substances

  • Antimetabolites, Antineoplastic
  • Nitric Oxide
  • Puromycin Aminonucleoside
  • Nitric Oxide Synthase